Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Trials
54%
Ramucirumab
51%
Risk Outcomes
51%
Patient Outcomes
51%
Risk-benefit
51%
Patient Benefit
51%
Drug Development
51%
Patient Risk
51%
Core Outcome Set
34%
Approved Indication
25%
Randomized Controlled Trial
23%
FDA-approved Drugs
19%
Clinical Trial Registry
17%
Reporting Guidelines
17%
Metabolism
17%
Diabetes
17%
Endocrinology
17%
Adverse Events
12%
Overall Survival
12%
Trialists
8%
Data Screening
8%
Screening Data
8%
Symptom Burden
7%
Efficacy Outcomes
6%
Oncology Drugs
6%
Positive Outcomes
6%
Medical Decision Making
6%
PubMed
6%
Evidence-based
6%
Excess Burden
6%
Off-label Indications
6%
Clinical Trial Failures
6%
Failure Rate
6%
Cochrane
6%
Embase
6%
Cancer Treatment
6%
MEDLINE
6%
Progression-free Survival
6%
Trial Participants
6%
Survival Benefit
6%
Gastric Cancer
6%
Poor Survival
6%
Literature Search
6%
Monotherapy
6%
Medicine and Dentistry
Clinical Trial
100%
Ramucirumab
51%
Endocrinology
34%
Randomized Controlled Trial
23%
Systematic Review
20%
Diabetes
17%
Student T Test
17%
Clinician
13%
Side Effect
12%
Adverse Event
12%
Overall Survival
12%
Drug Therapy
8%
Inferential Statistics
8%
Informed Consent
8%
Chi Square Test
8%
Human Subject
8%
Patient with Depression
8%
Awareness
8%
Patient Care
6%
Medical Decision Making
6%
Malignant Neoplasm
6%
Cancer Therapy
6%
Progression Free Survival
6%
Monotherapy
6%
Abdominal Cancer
6%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
64%
Drug Development
51%
Ramucirumab
51%
Randomized Controlled Trial
23%
Adverse Event
12%
Side Effect
12%
Overall Survival
12%
Malignant Neoplasm
12%
Progression Free Survival
6%
Abdominal Cancer
6%
Monotherapy
6%
